Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs. Reduces reliance on trial-and-error experimentation, shortens development timelines, and increases likelihood that pipeline candidates demonstrate robust binding and functional activity suitable for translational advancement. GT Biopharma anticipates multiple new development candidates moving into pre-IND development in 2027, with potential targets and indications expanding beyond oncology. SAN FRANCISCO, CALIFORNIA, June 01, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager TriKE® platform, today provided an update on its newly implemented AI-based technological initiatives and improved pipeline discovery efficiencies, which are expected to lead to additional development candidates advancing into pre-IND development in 2027. “We have seen a marked acceleration in our discovery productivity following recent initiatives implementing AI-based technologies, which have been adapted to improve our drug engineering capabilities,” said Michael Breen, Executive Chairman and Chief Executive Officer.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma, Inc. (NASDAQ: GTBP) is revolutionizing its drug discovery processes through advanced AI technologies. This innovative approach is expected to:
- Accelerate development timelines and reduce costs.
- Enhance the success rates of pipeline candidates.
- Enable the identification of new targets beyond oncology.
With multiple new candidates anticipated to move into pre-IND development by 2027, GT Biopharma is poised for significant growth in the immuno-oncology sector.
Why it matters: By utilizing AI, GT Biopharma not only speeds up its processes but potentially offers better therapeutic options for patients, a critical driver for investors.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.
